Evidence map›Paper›PMID 32558190›Full record

ReviewPediatric blood & cancer2020

Pediatric cancer research: Surviving COVID-19.

Jeffery J Auletta, Peter C Adamson, Jonathan E Agin, Pamela Kearns, Scott Kennedy, Mark W Kieran, Donna M Ludwinski, Leona J Knox, Kristi McKay, Pia Rhiner and 2 more

Abstract readReview
In one paragraph

Review in Pediatric blood & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Impact of COVID-19 on Pediatric Immunocompromised Patients.Pediatric clinics of North America · 2021
    Review
  10. Review
  11. Article
  12. Managing children with brain tumors during the COVID-19 era: Don't stop the care!Computational and structural biotechnology journal · 2021
    Review
  13. Pediatric cancer research: Surviving COVID-19.Pediatric blood & cancer · 2020
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jeffery J AulettaDivision of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.ORCID https://orcid.org/0000-0002-1515-2141
Peter C AdamsonOncology Development & Pediatric Innovation, Sanofi, Cambridge, Massachusetts.ORCID https://orcid.org/0000-0002-9487-757X
Jonathan E AginMax Cure Foundation, New York, New York.
Pamela KearnsEuropean Society of Paediatric Oncology, Brussels, Belgium.
Scott KennedySolving Kids' Cancer, New York, New York.
Mark W KieranBristol Myers Squibb, New York, New York.
Donna M LudwinskiSolving Kids' Cancer, New York, New York.
Leona J KnoxSolving Kids', Cancer, London, UK.
Kristi McKaySolving Kids' Cancer, New York, New York.
Pia RhinerSolving Kids' Cancer, New York, New York.
Carol J ThielePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Timothy P CripeDivision of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio.

Funding

Cancer Research UK 28028
6 · The paper itself

Abstract

A diverse panel of pediatric cancer advocates and experts, whose collective experience spans the continuum of international academic medicine, industry, government research, and cancer advocacy, recently discussed challenges for pediatric cancer research in the context of coronavirus disease 2019 (COVID-19). Specifically, this special report addresses the following focus areas: (a) the critical role that translational research has played in transforming pediatric cancer outcomes; (b) the current and potential future impact of COVID-19 on pediatric cancer research; (c) target areas of COVID-19 research that may have application in immunity, oncogenesis, and therapeutic discovery; and (d) future considerations and directions in maintaining pediatric cancer research during and after COVID-19.

Indexed as

Coronavirus InfectionsNeoplasmsPandemicsPneumonia, ViralTranslational Research, BiomedicalAdolescentBetacoronavirusChildChild, PreschoolCOVID-19FemaleHumansInfantMaleSARS-CoV-2advocacycancercoronavirusCOVID-19inflammationpediatricsrelapseresearchsystemic acute respiratory syndrometumor

Identifiers

PMID32558190
PMCPMC7323039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.